Inclusion Criteria:

          -  Histological or cytological diagnosis of metastatic squamous or non-squamous NSCLC.

          -  Life expectancy greater or equal to 3 months, as determined by the investigator
             -Patients must have progressed on the standard therapy, including platinum based -
             chemotherapy. Patients with epidermal growth factor receptor (EGFR), anaplastic
             lymphoma kinase (ALK), or ROS-1 mutations must have progressed on standard treatment
             options including EGFR, ALK, or ROS-1-directed therapies.

          -  No limits to the prior lines of treatment

          -  ECOG performance status of 0/1

          -  Measurable Disease by RECIST v1.1

          -  Age greater than 18 years.

          -  Adequate bone marrow, renal and hepatic function:

               -  Absolute neutrophil count (ANC) ≥ 1500 /µL

          -  White blood cell count (WBC) t ≥ 2.5 x 109/L (2500/µL)

               -  Lymphocyte count ≥ 0.5 x 109/L (500/µL)

          -  Platelet count ≥ 100 x 109/L (100,000/µL) without transfusion

          -  Hemoglobin ≥ (9.0 g/dL) - patients may be transfused to meet this criterion.

          -  Aspartate aminotransferase AST, alanine aminotransferase (ALT), and alkaline
             phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN)

               -  Serum bilirubin ≤ 1.5 x ULN, with the exception of patients with known Gilbert
                  disease: serum bilirubin level ≤ 3 x ULN

               -  Creatinine clearance >60 mL/min (calculated using the Cockcroft-Gault formula) or
                  by 24-hours urine collection

          -  Written informed consent and any locally-required authorization obtained from the
             subject prior to performing any protocol-related procedures, including screening
             evaluations

          -  Subject is willing and able to comply with the protocol for the duration of the study

        Exclusion Criteria:

          -  Participation in another clinical study with an investigational product during the
             last 4 weeks or 5 half-lives prior to starting on treatment.

          -  Symptomatic and/or untreated or actively progressing central nervous system (CNS)
             metastases or leptomeningeal disease. Patients with a history of treated CNS
             metastases are eligible, provided that all of the following criteria are met:

               -  The patient has not received stereotactic radiotherapy within 7 days prior to
                  initiation of study treatment or whole-brain radiotherapy within 14 days prior to
                  initiation of study treatment.

               -  The patient has no ongoing requirement for corticosteroids as therapy for CNS
                  disease. Anti-convulsant therapy at a stable dose is permitted.

          -  Serious uncontrolled medical disorder or active infection that would impair the
             patient's ability to receive study treatment.

          -  Concurrent use of other anticancer approved or investigational agents is not allowed.

          -  Autoimmune disorder

          -  Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol

          -  Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within
             the past 2 years) are not excluded.

          -  Patients receiving systemic steroids ≥ 10mg/day of prednisone or the equivalent

          -  Smoking (cigarettes, cigars or pipes) must be discontinued at least 7 days prior to
             initiating study drug administration; smoking cessation products (transdermal nicotine
             patches or chewing gum may be used.

          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the study. Female
             subjects must either be of non-reproductive potential or have a negative serum
             pregnancy test result within 14 days prior to initiation of study treatment